Leidi.com Lei Jianping June 29
Laikai Pharmaceutical Co., Ltd. (abbreviation: "Laikai Pharmaceutical", stock code: "02105") was listed on the Hong Kong Stock Exchange today.
The issue price of Laikai Medicine is HK$12.41, and the net fundraising amount is HK$708 million.
The cornerstone investors of Laikai Medical include Yuyao Yangming Equity Investment Fund Co., Ltd., FIIF, Yanchuang Chenkai and OrbiMed, which subscribed a total of 680 million Hong Kong dollars, accounting for 86% of the total fundraising.
Among them, Yuyao Yangming Equity Investment Fund Co., Ltd. subscribed for 472 million Hong Kong dollars, FIIF subscribed for 118 million Hong Kong dollars, Yan Chuang Chenkai subscribed for 66.84 million Hong Kong dollars, and OrbiMed subscribed for 3 million US dollars.
Dr. Lu Xiangyang, the founder, chairman and CEO of Laikai Pharmaceutical Co., Ltd. said: "The successful listing on the Hong Kong Stock Exchange means that Laikai has entered the stage of the international capital market. This is an important milestone for the company's development. It is a new starting point.
Laikai Pharmaceutical opened
Annual operating loss of 393 million
Founded in December 2016, Laikai Medicine is located in Zhangjiang Hi-Tech Park, Shanghai, and is committed to bringing innovative therapies to cancer and liver disease patients around the world.
At present, there are 14 innovative drug candidates in the company's product pipeline, and 6 projects have been approved for clinical research, all of which are aimed at the urgent and unmet medical needs of drug resistance in current tumor treatment, including 3 international multi-center clinical trials ( Including 1 pivotal clinical trial).
According to the prospectus, the revenue of Laikai Medicine in 2021 and 2022 will be 520,000 and 4.8 million respectively; operating losses will be 226 million and 393 million respectively; losses during the year will be 749 million and 792 million respectively.
Among them, the change in fair value of financial instruments issued by Laikai Pharmaceutical to investors in 2021 is -522 million yuan, and the change in fair value in this regard in 2022 is -387 million yuan.
As of December 31, 2022, the cash and cash equivalents held by Laikai Medicine are 323 million yuan.
OrbiMed and SDIC China Merchants are shareholders
The executive directors of Laikai Medicine are Dr. Lu Xiangyang, Ms. Xie Ling, and Dr. Gu Xiangju; the non-executive directors are Dr. Wang Guowei, Ms. Ji Dongmei, and Sun Yuan; the independent non-executive directors are Dr. Yin Xudong, Zou Guoqiang, and Li Min. PhD. Dr. Lu Xiangyang is an American.
In March 2020, Laikai Medical completed the B round of financing with a total amount of 27.5 million US dollars. The investment was led by Jinpu Health Fund and followed by the original investor OrbiMed Asia.
In March 2021, Laikai Medicine completed the C round of financing with a total amount of 61 million US dollars;
In May 2022, Laikai Pharmaceutical announced the completion of the D round of financing of US$61 million (approximately 390 million). This round of financing was led by SDIC China Merchants. .
Before the IPO, OrbiMed Asia held 16.98%, Dr. Lu held 14.55%, ESOP Trust held 14.27%, and Shanghai Jinpu Medical Health's GP entity held 12%.
Beijing Anlong holds 6.61% of the shares, Shenzhen Investment Entity holds 5.61% of the shares, Advanced Manufacturing Industry Investment Fund Phase II holds 5.58% of the shares, and Rococean holds 4.66% of the shares;
Yanyuan Group holds 4.40%, Novartis Pharma holds 2.76%, CMBI Private holds 2.31%, and Linbell holds 2.2%.
———————————————
Lei Di was founded by Lei Jianping, a media person. If you reprint, please indicate the source.
